Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)

被引：0
|
作者：
Loriot, Yohann
Matsubara, Nobuaki
Park, Se Hoon
Huddart, Robert A.
Burgess, Earle F.
Houede, Nadine
Banek, Severine
Laguerre, Brigitte
Guadalupi, Valentina
Ku, Ja Hyeon
Triantos, Spyros
Akapame, Sydney
Deprince, Kris
Mukhopadhyay, Sutapa
Siefker-Radtke, Arlene O.
机构：
[1] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, INSERM 981, Villejuif, France
[2] Natl Canc Ctr Hosp East, Dept Med Oncol, Chiba, Japan
[3] Sungkyunkwan Univ, Samsung Med Ctr, Gangnam, South Korea
[4] Inst Canc Res, Sect Radiotherapy & Imaging, Sutton, Surrey, England
[5] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[6] Atrium Hlth, Levine Canc Inst, Charlotte, NC USA
[7] CHU Caremeau, Inst Cancerol Gard, Dept Med Oncol, Nimes, France
[8] Goethe Univ, Univ Hosp Frankfurt, Dept Urol, Frankfurt, Germany
[9] Ctr Eugene Marquis, Dept Med Oncol, Rennes, France
[10] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[11] Seoul Natl Univ Hosp, Seoul, South Korea
[12] Janssen Res & Dev, Spring House, PA USA
[13] Janssen Res & Dev, Beerse, Belgium
[14] Janssen Res & Dev, Lexington, MA USA
[15] Univ Texas MD Anderson Canc Ctr, Dept Genitourinary Med Oncol, Houston, TX USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 17期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
LBA4619
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)
    Banek, S.
    Loriot, Y.
    Matsubara, N.
    Park, S. H.
    Huddart, R. A.
    Burgess, E. F.
    Houede, N.
    Laguerre, B.
    Guadalupi, V
    Ku, J. H.
    Triantos, S.
    Akapame, S.
    Deprince, K.
    Mukhopadhyay, S.
    Siefker-Radtke, A. O.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 94 - 94
  • [2] Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).
    Matsubara, Nobuaki
    Park, Se Hoon
    Huddart, Robert A.
    Burgess, Earle F.
    Houede, Nadine
    Banek, Severine
    Laguerre, Brigitte
    Guadalupi, Valentina
    Ku, Ja Hyeon
    Triantos, Spyros
    Akapame, Sydney
    Deprince, Kris
    Mukhopadhyay, Sutapa
    Siefker-Radtke, Arlene O.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (17_SUPPL) : LBA4619 - LBA4619
  • [3] Phase III THOR study: Results of erdafitinib (erda) vs pembrolizumab (pembro) in pretreated patients (pts) with advanced or metastatic urothelial cancer (muc) with select fibroblast growth factor receptor alterations (FGFRalt)
    Siefker-Radtke, A. O.
    Matsubara, N.
    Park, S. H.
    Huddart, R. A.
    Burgess, E. F.
    Ozguroglu, M.
    Perez Valderrama, B.
    Triantos, S.
    Akapame, S.
    Kean, Y.
    Deprince, K.
    Mukhopadhyay, S.
    Loriot, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S1199 - S1199
  • [4] Erdafitinib (erda) vs chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select FGFR alterations (FGFRalt): Subgroups from the phase III THOR study
    Loriot, Y.
    Matsubara, N.
    Huddart, R. A.
    Houede, N.
    Laguerre, B.
    Guadalupi, V.
    Ku, J. H.
    Triantos, S.
    Akapame, S.
    Deprince, K.
    Mukhopadhyay, S.
    Siefker-Radtke, A. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S1201 - S1201
  • [5] Asian subgroup analysis of the THOR phase III study: Erdafitinib versus chemotherapy in patients with advanced or metastatic urothelial cancer and selected fibroblast growth factor receptor alterations
    Matsubara, N.
    Loriot, Y.
    Burgess, E. F.
    Park, S. H.
    Huddart, R. A.
    Ku, J. H.
    Tran, B.
    Triantos, S.
    Deprince, K.
    Mukhopadhyay, S.
    Hemaya, R.
    Zhuo, J.
    Siefker-Radtke, A. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S1556 - S1556
  • [6] Phase 3 THOR Japanese subgroup analysis: erdafitinib in advanced or metastatic urothelial cancer and fibroblast growth factor receptor alterations
    Matsubara, Nobuaki
    Miura, Yuji
    Nishiyama, Hiroyuki
    Taoka, Rikiya
    Kojima, Takahiro
    Shimizu, Nobuaki
    Hwang, Jason
    Ote, Tatsuya
    Oyama, Ryo
    Toyoizumi, Kiichiro
    Mukhopadhyay, Sutapa
    Triantos, Spyros
    Deprince, Kris
    Loriot, Yohann
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (10) : 1516 - 1527
  • [7] Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA plus CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study
    Siefker-Radtke, Arlene O.
    Powles, Thomas
    Moreno, Victor
    Kang, Taek Won
    Cicin, Irfan
    Girvin, Angela
    Akapame, Sydney
    Triantos, Spyros
    O'Hagan, Anne
    Zhu, Wei
    Tammaro, Meggan
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
    Powles, T. B.
    Chistyakov, V.
    Beliakouski, V.
    Semenov, A.
    Everaert, E.
    Baranau, Y.
    Moreno, V.
    Valderrama, B. Perez
    Vano, Y.
    Del Conte, G.
    Loriot, Y.
    Kang, T. W.
    Tammaro, M.
    O'Hagan, A.
    Hosseini, M.
    Triantos, S.
    Chhabra, H.
    Santiago-Walker, A.
    Siefker-Radtke, A. O.
    ANNALS OF ONCOLOGY, 2021, 32 : S1303 - S1303
  • [9] First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt).
    Siefker-Radtke, Arlene O.
    Necchi, Andrea
    Park, Se Hoon
    GarcAa-Donas, JesAs
    Huddart, Robert A.
    Burgess, Earle Frederick
    Fleming, Mark T.
    Rezazadeh, Arash
    Mellado, Begona
    Varlamov, Sergei
    Joshi, Monika
    Duran, Ignacio
    Tagawa, Scott T.
    OHagan, Anne
    Avadhani, Anjali Narayan
    Zhong, Bob
    De Porre, Peter
    Loriot, Yohann
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [10] Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations
    Siefker-Radtke, A. O.
    Loriot, Y.
    Siena, S.
    Beato, C.
    Climent Duran, M. A.
    Varlamov, S.
    Duran, I.
    Tagawa, S. T.
    Geoffrois, L.
    Mellado, B.
    Semenov, A.
    Delva, R.
    Lykov, A. P.
    Dirix, L. Y.
    Akapame, S.
    O'Hagan, A.
    Tammaro, M.
    Mosher, S.
    Kang, T. W.
    Moreno, V.
    ANNALS OF ONCOLOGY, 2020, 31 : S584 - S585
12345